Humacyte, Inc. (NASDAQ:HUMA) Receives Average Rating of “Buy” from Analysts

Shares of Humacyte, Inc. (NASDAQ:HUMA) have been assigned a consensus rating of “Buy” from the eight research firms that are covering the company, MarketBeat reports. One analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $11.71.

A number of research firms have commented on HUMA. D. Boral Capital reissued a “buy” rating and set a $25.00 price target on shares of Humacyte in a report on Monday, June 9th. HC Wainwright started coverage on Humacyte in a report on Wednesday, May 14th. They issued a “buy” rating and a $4.00 target price on the stock. Benchmark reduced their target price on Humacyte from $17.00 to $14.00 and set a “buy” rating on the stock in a report on Wednesday, May 14th. Finally, Wall Street Zen raised Humacyte from a “sell” rating to a “hold” rating in a report on Friday, June 27th.

Insider Activity

In related news, CFO Dale A. Sander purchased 20,000 shares of the company’s stock in a transaction that occurred on Thursday, April 10th. The stock was bought at an average price of $1.53 per share, for a total transaction of $30,600.00. Following the completion of the transaction, the chief financial officer owned 40,600 shares in the company, valued at approximately $62,118. The trade was a 97.09% increase in their position. The purchase was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Kathleen Sebelius purchased 50,000 shares of the company’s stock in a transaction that occurred on Tuesday, April 8th. The stock was bought at an average price of $1.32 per share, with a total value of $66,000.00. Following the transaction, the director owned 91,207 shares of the company’s stock, valued at $120,393.24. This represents a 121.34% increase in their position. The disclosure for this purchase can be found here. In the last quarter, insiders purchased 83,993 shares of company stock valued at $118,224. 5.10% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Endowment Wealth Management Inc. boosted its position in shares of Humacyte by 3.6% during the fourth quarter. Endowment Wealth Management Inc. now owns 104,108 shares of the company’s stock valued at $526,000 after buying an additional 3,590 shares during the period. Beacon Pointe Advisors LLC boosted its position in shares of Humacyte by 33.3% during the fourth quarter. Beacon Pointe Advisors LLC now owns 20,000 shares of the company’s stock valued at $101,000 after buying an additional 5,000 shares during the period. Teacher Retirement System of Texas boosted its position in shares of Humacyte by 25.3% during the fourth quarter. Teacher Retirement System of Texas now owns 26,200 shares of the company’s stock valued at $132,000 after buying an additional 5,293 shares during the period. Price T Rowe Associates Inc. MD boosted its position in shares of Humacyte by 20.7% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 33,870 shares of the company’s stock valued at $172,000 after buying an additional 5,801 shares during the period. Finally, MetLife Investment Management LLC boosted its position in shares of Humacyte by 14.4% during the first quarter. MetLife Investment Management LLC now owns 51,442 shares of the company’s stock valued at $88,000 after buying an additional 6,482 shares during the period. Hedge funds and other institutional investors own 44.71% of the company’s stock.

Humacyte Price Performance

NASDAQ:HUMA opened at $2.27 on Monday. The company has a quick ratio of 3.28, a current ratio of 3.68 and a debt-to-equity ratio of 0.36. The business’s 50-day simple moving average is $2.14 and its two-hundred day simple moving average is $2.94. The stock has a market cap of $351.35 million, a PE ratio of -3.28 and a beta of 1.89. Humacyte has a 52 week low of $1.15 and a 52 week high of $9.79.

Humacyte (NASDAQ:HUMA) last posted its quarterly earnings results on Tuesday, May 13th. The company reported ($0.10) EPS for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.09. The business had revenue of $0.52 million for the quarter, compared to the consensus estimate of $0.46 million. As a group, analysts forecast that Humacyte will post -1.27 EPS for the current fiscal year.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.